Fetal Urinary Tract Obstruction: Vesicoamniotic Shunt Outcomes

Fetal urinary tract obstruction is a serious pregnancy complication in which urine cannot pass normally from the fetal bladder into the amniotic cavity. The obstruction may cause an enlarged bladder, reduced amniotic fluid, kidney damage and impaired lung development. The condition is often called lower urinary tract obstruction, or LUTO, when the blockage occurs below the bladder.

A vesicoamniotic shunt is a small catheter placed through the fetal bladder wall and into the amniotic sac. Its purpose is to create an alternative route for urine drainage, restore amniotic fluid and give the developing lungs a better environment. The procedure can be technically successful while still producing an uncertain long-term result, so counselling must cover both immediate and later outcomes.

Families in Australia may be referred from a regional maternity service to a tertiary fetal medicine centre in Sydney, Melbourne, Brisbane, Adelaide or Perth. Decisions are made by a multidisciplinary team, often involving maternal-fetal medicine specialists, fetal surgeons, neonatologists, paediatric urologists and genetic counsellors. The FAOPS 2020 congress site provides historical context for the wider perinatal and neonatal research community in which these questions have been discussed.

Understanding Fetal Urinary Tract Obstruction

LUTO is most frequently associated with posterior urethral valves in a male fetus, although urethral atresia and other structural abnormalities can produce a similar pattern. Ultrasound may show a persistently enlarged bladder, thickened bladder walls and the classic “keyhole” appearance caused by dilation of the posterior urethra. Hydronephrosis and abnormal-looking kidneys may also be present.

The amount of amniotic fluid is a major concern because fetal urine becomes an important source of fluid after the middle of pregnancy. Severe oligohydramnios or anhydramnios can restrict lung growth, leading to pulmonary hypoplasia. Kidney injury may begin early and can be irreversible before treatment is considered.

Diagnosis is based on repeated ultrasound rather than a single scan. Clinicians assess bladder size and emptying, kidney structure, amniotic fluid volume, fetal growth, Doppler findings and the presence of other anomalies. A detailed assessment is essential because an isolated obstruction has a different outlook from obstruction accompanied by chromosomal, cardiac or multisystem abnormalities.

How Vesicoamniotic Shunts Are Used

A vesicoamniotic shunt is generally considered when there is severe, apparently isolated lower urinary tract obstruction, reduced amniotic fluid and a gestational age at which fetal treatment may offer meaningful benefit. The procedure is usually performed under ultrasound guidance, with a needle passing through the maternal abdomen and uterine wall into the fetal bladder. One end of the catheter sits in the bladder and the other in the amniotic cavity.

The shunt does not remove the underlying blockage. It is intended to decompress the bladder and replenish the fluid around the fetus. In some cases, the catheter becomes displaced, blocked or expelled as the pregnancy progresses. A repeat procedure may be required, and the pregnancy still needs close ultrasound surveillance.

Selection is difficult because an apparently severe obstruction may coexist with enough preserved kidney function for survival, while a technically successful drainage procedure may come too late to reverse established renal or pulmonary damage. Tests of fetal urine biochemistry have been investigated, but their predictive value is imperfect. Kidney appearance, bladder behaviour and the overall clinical picture remain central to counselling.

What Outcomes Can Families Expect

The main potential benefit is improved survival through better lung development. Restoring amniotic fluid may reduce the risk of lethal pulmonary hypoplasia, particularly when treatment occurs before prolonged severe fluid loss. Observational studies have reported improved perinatal survival in selected fetuses, but outcomes vary greatly between centres and patient groups.

Evidence from randomised and prospective research has been more cautious. The PLUTO trial found that vesicoamniotic shunting did not produce a clear overall survival advantage in the full study population, although the number of participants was limited and possible benefit was suggested among babies who survived to birth. This means families should not be given a simple promise that drainage will prevent kidney failure or guarantee survival.

Survivors commonly need neonatal and paediatric urology care. A baby with posterior urethral valves may require bladder drainage, cystoscopy and valve ablation after birth. Long-term issues can include recurrent urinary tract infections, vesicoureteric reflux, poor bladder compliance, hypertension, chronic kidney disease and, in severe cases, dialysis or kidney transplantation.

Comparing Treatment Goals And Results

The table below summarises the outcomes clinicians usually discuss. It separates the immediate objective of a shunt from the longer-term results that depend on the original severity of obstruction and the degree of kidney injury already present.

Counselling should therefore distinguish technical success from meaningful clinical benefit. Seeing urine pass through the catheter is encouraging, but it does not confirm normal kidney function or eliminate the risk of respiratory problems. Similarly, a normal amount of fluid later in pregnancy does not guarantee normal renal development.

Perinatal teams may discuss termination of pregnancy, expectant management, fetal intervention or palliative care, depending on gestational age, local law, fetal condition and family values. In Australia, access pathways and referral arrangements can differ between states and territories, particularly for families travelling from rural or remote communities.

Risks And Practical Decision-Making

Maternal risks from the procedure are usually low but can include bleeding, infection, membrane rupture and complications related to anaesthesia. Fetal and pregnancy risks include shunt blockage, displacement, bowel or cord injury, fetal bleeding, chorioamnionitis, preterm premature rupture of membranes and premature birth. The possibility of needing an urgent caesarean birth or prolonged hospital care should be included in the discussion.

The procedure is also associated with uncertainty. Some fetuses have a good lung response but later develop substantial kidney disease. Others may have such advanced renal or pulmonary damage that drainage does not change the outcome. A second shunt or other fetal procedure may be offered in selected circumstances, although each intervention adds procedural risk.

Families benefit from a written plan covering warning signs, travel, accommodation, ultrasound frequency and the location of delivery. Australian patients may need to use state-based travel assistance schemes when attending a metropolitan fetal medicine unit. A family living several hours from a centre in regional New South Wales, Queensland or Western Australia may need to relocate before delivery, particularly if membrane rupture or preterm labour becomes likely.

Antenatal corticosteroids may be recommended when preterm birth is considered possible, but the timing depends on gestational age and the immediate clinical picture. Background discussion of fetal lung maturity and corticosteroid treatment is available in this fetal lung maturity guidance. Steroids support lung maturation; they do not repair kidney injury or replace the need for neonatal respiratory planning.

Care In Australia Before And After Birth

Antenatal care is best coordinated through a fetal medicine service attached to a tertiary hospital with neonatal intensive care and paediatric urology. The Royal Women’s Hospital in Melbourne, Westmead and Royal Prince Alfred in Sydney, the Mater in Brisbane, Women’s and Children’s Hospital in Adelaide and King Edward Memorial Hospital in Perth are examples of major referral settings, although local pathways and availability change.

The delivery plan should identify the neonatal team, likely respiratory support, the need for bladder catheterisation and the timing of postnatal imaging. After birth, ultrasound and a voiding cystourethrogram may be used to assess the urinary tract. Cystoscopy can confirm and treat posterior urethral valves when the infant is stable enough for the procedure.

Australian families may encounter different terminology between public hospitals, private obstetric services and interstate referral centres. Medicare generally supports medically necessary public hospital care, while travel, accommodation, private fees and time away from work may require separate planning. For Aboriginal and Torres Strait Islander families, culturally safe care and involvement of Aboriginal Liaison Officers can help make long-distance referral and hospital decisions more manageable.

Long-term follow-up should include kidney function, blood pressure, growth, urine testing and bladder health. Some children appear well during infancy but develop reduced kidney function later, so ongoing review is important. Parents should receive clear advice about fever, reduced urine output, feeding problems and urinary infection, along with a named service to contact.

A specialist discussion should be arranged promptly when ultrasound shows a persistently enlarged fetal bladder, reduced amniotic fluid or suspected urinary tract obstruction. Ask the treating team to explain the severity of the obstruction, the condition of both kidneys, the expected risks of shunting and the neonatal plan in plain language. Early referral gives families more time to consider the available options, organise travel and make decisions that reflect their values.